Gt biopharma and fate therapeutics present preclinical data highlighting novel dual antigen targeting approach for the treatment of aml at ash 2022

Presentation shows the therapeutic potential of combining ipsc-derived car nk cells and nk cell engagers to overcome the clinical heterogeneity of aml

GTBP Ratings Summary

GTBP Quant Ranking